Tag: CBT > FDA Policy on CBD: Page 4

Finance

CV Sciences Reveals FY 2019 Earnings, Discusses Future Amid Coronavirus Outbreak

In a recent earnings call, company executives discussed challenges they endured in 2019 and what they're facing in 2020.

March 19, 2020

Compliance

Washington Lawmaker Introduces Bill to Allow CBD in Food

Rep. Drew MacEwen’s bill conflicts with federal regulations, as well as a warning from the Washington State Department of Agriculture.

January 13, 2020

Legislation and Regulation

Akers Bio Forms Advisory Board to Explore Involvement in the Hemp and Minor Cannabinoid Market

Recent FDA statements on the danger of CBD products in the open market and the need for DEA-regulated testing have given companies like Akers Bio an opportunity to explore a role in hemp and minor cannabinoid testing and processing.

December 6, 2019

Interviews & Opinion

AmourCBD Secures FDA Registration to Earn Customer Trust

The company has registered its CBD topical cream with the FDA to differentiate itself in the crowded marketplace.

November 7, 2019

Legislation and Regulation

Senate Committee Hearing Emphasizes the Need for Policy Change to Increase Cannabis Research Access

This week, Senators Feinstein and Cornyn convened a panel of leading health experts to uncover the health impact of cannabis on consumers. Instead, they were hit with the realization that the only way to determine those impacts is through increased research access.

October 25, 2019

2018 Farm Bill Status

How Far Has CBD Come Since the Passage of the 2018 Farm Bill?

From the FDA’s first-ever hearing on CBD to major retail chains carrying infused products, here is a summary of how hemp and CBD have progressed since federal legalization.

August 8, 2019

Compliance

Curaleaf Scrubs CBD Health Claims From Its Pages in Response to FDA Warning

Curaleaf “immediately began an extensive review of its website and social media platforms to remove all statements that FDA identified as non-compliant.”

July 29, 2019

Legislation and Regulation

FDA Issues Warning to Curaleaf for 'Unsubstantiated' CBD Health Claims

The warning letter included some examples of how Curaleaf Hemp products have been marketed on the company's social media accounts.

July 24, 2019

Industry Headlines

Former FDA Chief Scott Gottlieb Says Some Claims About Health Benefits of CBD Are ‘Pretty Hokey’

CBD is not a “benign compound,” and regulations will be needed to protect people from possible unknown side effects, Gottlieb said.

June 18, 2019